Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ayumi Chief Says Contender Debut Will Add Vigor to Enbrel Biosimilar Space, Sees Govt Fee Incentive as Booster
Back in FY2018, Ayumi Pharmaceutical was hit by an unexpected supply hitch due to spiking demand for its Enbrel (etanercept) biosimilar, which was then Japan’s only follow-on for the major rheumatoid arthritis (RA) drug. With manufacturing ramped up, President Kiyonori…
To read the full story
Related Article
- Ayumi to Ease Restrictions on Enbrel Biosimilar Use as Product Boost Progresses
July 24, 2019
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
October 19, 2018
- Japan’s 1st Enbrel Biosimilar Makes Its Debut
May 31, 2018
- Mochida’s Enbrel Biosimilar Approved, with Ayumi as Distributor
January 22, 2018
- Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
BUSINESS
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
- Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
- Xospata Misses OS Endpoint in PIII Trial in Untreated FLT3-Mutated AML
March 10, 2026
- Enhertu Now under US Review for Post-Neoadjuvant HER2 Breast Cancer
March 10, 2026
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…